Viewing data from:

TRI-LEGEST FE

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | A076105 | BARR LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Tri-Legest Fe (2023)

Total Spending

$27K

Total Claims

414

Beneficiaries

Avg Cost/Unit

$1.33

Spending Trend

$58K(2019)→$56K(2020)→$55K(2021)→$37K(2022)→$27K(2023)

YoY Change:-2.6%

5yr CAGR:-1.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Oct 26, 2007

No patent or exclusivity listings for this strength.